AR043054A1 - Derivados de piperazina que actuan como ligandos receptores de melanocortina y composiciones farmaceuticas que los contienen para controlar trastornos mediados por mc-4 - Google Patents

Derivados de piperazina que actuan como ligandos receptores de melanocortina y composiciones farmaceuticas que los contienen para controlar trastornos mediados por mc-4

Info

Publication number
AR043054A1
AR043054A1 ARP030103859A ARP030103859A AR043054A1 AR 043054 A1 AR043054 A1 AR 043054A1 AR P030103859 A ARP030103859 A AR P030103859A AR P030103859 A ARP030103859 A AR P030103859A AR 043054 A1 AR043054 A1 AR 043054A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
mixtures
group
index
Prior art date
Application number
ARP030103859A
Other languages
English (en)
Inventor
Frank Hallock Ebetino
Xinrong Tian
Wieslaw Adam Mazur
Anny-Odile Colson
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of AR043054A1 publication Critical patent/AR043054A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)

Abstract

Un compuesto, incluyendo todas las formas enantioméricas y diastereoméricas y las sales farmacéuticamente aceptables de éstas, el compuesto antes mencionado tiene la fórmula (1), en donde L representa una unidad de enlace cada una de las cuales independientemente se selecciona del grupo que consiste de: a) -(R2)p(CH=CH)q-; b) -(R2)y(X)zC(Y)w(X)z(R2)y-; c) -(R2)y(X)zS(Y)k(X)z(R2)y-; d) -(R2)y(Z)mNR4(Z)m(R2)y-; e) -(R2)y(O)2P(T)k(O)z(R2)y-; en donde T es =O, -OR4, y mezclas de estos; en donde X es -O-, -S-, -NR4-; Y es =O, =S, =NR4, -R4, y mezclas de estos; Z es =N-, -NR4-, y mezclas de estos; el índice k es desde 0 a 2; el índice m es 0 ó 1; el índice p es desde 0 a 12; el índice q es desde 0 a 3; el índice w es desde 0 a 2; el índice y es 0 ó 1; el índice z es 0 ó 1; cada R2 independientemente es una unidad de metileno sustituido o no sustituido representada por la fórmula -[CR3aR3b]- en donde R3a y R3b cada una independientemente se selecciona del grupo que consiste de: i) hidrógeno; ii) C1-12 hidrocarbilo que se selecciona del grupo que consiste de: a) alquilo C1-12 lineal o ramificado, sustituido o no sustituido; b) cicloalquilo C3-12 sustituido o no sustituido; c) alquenilo C2-12 lineal o ramificado, sustituido o no sustituido; d) cicloalquenilo C3-12 sustituido o no sustituido; e) arilo C6-C12 sustituido o no sustituido; f) heterociclo C1-12 sustituido o no sustituido; g) heteroarilo C3-12, sustituido o no sustituido; h) y mezclas de estos; iii) -[C(R11)2]nCOR4; iv) -[C(R11)2]nCOOR4; v) -[C(R11)2]nCOCH=CH2; vi) -[C(R11)2]nC(=NR4)N(R4)2; vii) -[C(R11)2]nCON(R4)2; viii) -[C(R11)2]nCONR4N(R4)2; ix) -[C(R11)2]nCN; x) -[C(R11)2]nCNO; xi) -[C(R11)2]nCF3, -[C(R11)2]nCCl3, -[C(R11)2]nCBr3; xii) -[C(R11)2]nN(R4)2; xiii) -[C(R11)2]nNR4COR4; xiv) -[C(R11)2]nNR4CN; xv) -[C(R11)2]nNR4C(=NR4)N(R4)2; xvi) -[C(R11)2]nNHN(R4)2; xvii) -[C(R11)2]nNHOR4; xviii) -[C(R11)2]nNCS; xix) -[C(R11)2]nNO2; xx) -[C(R11)2]nOR4; xxi) -[C(R11)2]nOCN; xxii) -[C(R11)2]nOCF3, -[C(R11)2]nOCCl3, -[C(R11)2]nOCBr3; xxiii) F, Cl, Br, I, y mezclas de estos; xxiv) -[C(R11)2]nSO3M; xxv) -[C(R11)2]nOSO3M; xxvi) -[C(R)2]nSCN; xxvii) -[C(R11)2]nSO2N(R4)2; xxviii) -[C(R11)2]nSO2R4; xxix) -[C(R11)2]nP(O)(OR4)R4; xxx) -[C(R11)2]nP(O)(OR4)2; xxxi) haloalquilo que tiene la fórmula -[C(R9)2]nC(R9)3; xxxii) una unidad R3a y una unidad R3b del mismo átomo de carbono se pueden tomar juntas para formar un anillo carbocíclico o heterocíclico que comprende de 3 a 8 átomos; xxxiii) una unidad R3a ó R3b de una primera unidad R2 se puede tomar junto con una unidad R3a ó R3b de una segunda unidad R2 para formar un anillo carbocíclico o heterocíclico que comprende 3 a 8 átomos; xxxiv) y mezclas de estos; R9 es hidrógeno, flúor, cloro, bromo, iodo, y mezclas de estos; cada R11 es hidrógeno ó R10; el índice n tiene el valor de 0 a 10; las unidades R4 son unidades de hidrocarbilo cada una de las cuales independientemente se selecciona del grupo que consiste de: i) hidrógeno; ii) hidrocarbilo C1-12 que se selecciona del grupo que consiste de: a) alquilo C1-12 lineal o ramificado, sustituido o no sustituido; b) cicloalquilo C3-12 sustituido o no sustituido; c) alquenilo C2-12 lineal o ramificado, sustituido o no sustituido; d) cicloalquenilo C3-12 sustituido o no sustituido; e) arilo C6-12 sustituido o no sustituido; f) heterociclo C1-12 sustituido o no sustituido; g) heteroarilo C3-12 sustituido o no sustituido; h) y mezclas de estos; R es una unidad de hidrocarbilo sustituido o no sustituido que se selecciona del grupo que consiste de: a) anillos carbocíclicos no aromáticos; b) anillos carbocíclicos aromáticos; c) anillos heterocíclicos no aromáticos; d) anillos heterocíclicos aromáticos; W es una unidad pendiente que tiene la fórmula: -(L)r-[CR5aR5b]x-Q en donde el índice r es 0 ó 1 y el índice x es de 0 a 10; Q es: a) hidrógeno; b) -N(R4)2; c) -OR4; d) una unidad que comprende una unidad sustituida o no sustituida que se selecciona del grupo que consiste de: i) anillos carbocíclicos no aromáticos; ii) anillos carbocíclicos aromáticos; iii) anillos heterocíclicos no aromáticos; iv) anillos heterocíclicos aromáticos; en donde el número de anillos es de 1 a 3; R5a y R5b cada uno independientemente se selecciona del grupo que consiste de i) hidrógeno; ii) hidrocarbilo C1-12 que se selecciona del grupo que consiste de: a) alquilo C1-12 lineal o ramificado, sustituido o no sustituido; b) cicloalquilo C3-12 sustituido o no sustituido; c) alquenilo C2-12 lineal o ramificado, sustituido o no sustituido; d) cicloalquenilo C3-12 sustituido o no sustituido; e) arilo C6-12 sustituido o no sustituido; f) heterociclilo C1-12 sustituido o no sustituido; g) heteroarilo C3-12 sustituido o no sustituido; h) y mezclas de estos; iii) -[C(R11)2]nCOR4; iv) -[C(R11)2]nCOOR4; v) -[C(R11)2]nCOCH=CH2; vi) -[C(R11)2]nC(=NR4)N(R4)2; vii) -[C(R11)2]nCON(R4)2; viii) -[C(R11)2]nCONR4N(R4)2; ix) -[C(R11)2]nCN; x) -[C(R)2]nCNO; xi) -[C(R11)2]nCF3, -[C(R11)2]nCCl3, -[C(R11)2]nCBr3; xii) -[C(R11)2]nN(R4)2; xiii) -[C(R11)2]nNR4COR4; xiv) -[C(R11)2]nNR4CN; xv) -[C(R11)2]nNR4C(=NR4)N(R4)2; xvi) -[C(R11)2]nNHN(R4)2; xvii) -[C(R11)2]nNHOR4; xviii) -[C(R11)2]nNCS; xix) -[C(R11)2]nNO2; xx) -[C(R11)2]nOR4; xxi) -[C(R11)2]nOCN ; xxii) -[C(R11)2]nOCF3, -[C(R11)2]nOCCl3, -[C(R11)2]nOCBr3; xxiii) F, Cl, Br, I, y mezclas de estos; xxiv) -[C(R11)2]nSO3M; xxv) -[C(R11)2]nOSO3M; xxvi) -[C(R11)2]nSCN; xxvii) -[C(R11)2]nSO2N(R4)2; xxviii) -[C(R11)2]nSO2R4; xxiv) -[C(R11)2]nP(O)(OR4)R4; xxx) -[C(R11)2]nP(O)(OR4)2; xxxi) haloalquilo que tiene la fórmula -[C(R9)2]nC(R9)3; xxxii) R5a y R5b se pueden tomar juntos para formar un anillo carbocíclico o heterocíclico que comprende de 3 a 10 átomos; xxxiii) y mezclas de estos; R1 es alquilo C1-12 lineal o ramificado, sustituido o no sustituido, alquilo C3-8 cíclico, alquenilo C2-12 lineal o ramificado, o -[C(R9)2]nC(R9)3; R9 es hidrógeno, flúor, cloro, bromo, iodo, y mezclas de estos; el índice n tiene el valor de 0 a 10 como se define anteriormente en la presente invención; A, A1, y A2 son componentes de anillo cada uno de los cuales se selecciona independientemente del grupo que consiste de -C(=NR6)-, -C(=O)-, -C(=S)-, -C(R6)2-, -C(R6)2C(R6)2-, -CR6=, -N=, -NR6-, ó dos unidades A se pueden tomar juntas con un átomo adyacente o una unidad para formar un enlace que tiene la fórmula -N=N-, -N-NR6-, -CR6=N-, -C=N-, y mezclas de estos; el índice j es 0 ó 1; R6 es hidrógeno, R4, ó la unidad pendiente W1 que tiene la fórmula -(L)r-[CR7aR7b]x-R8 en donde el índice r es igual a 0 ó 1; R7a y R7b cada uno independientemente se selecciona del grupo que consiste de i) hidrógeno; ii) hidrocarbilo C1-12 que se selecciona del grupo que consiste de: a) alquilo C1-12 lineal o ramificado, sustituido o no sustituido; b) cicloalquilo C3-12 sustituido o no sustituido; c) alquenilo C2-C12 lineal o ramificado, sustituido o no sustituido; d) cicloalquenilo C3-12 sustituido o no sustituido; e) arilo C6-12 sustituido o no sustituido; f) heterociclilo C1-12 sustituido o no sustituido; g) heteroarilo C3-12 sustituido o no sustituido; h) y mezclas de estos; iii) -[C(R11)2]nCOR4; iv) -[C(R11)2]nCOOR4; v) -[C(R11)2]nCOCH=CH2; vi) -[C(R11)2]nC(=NR4)N(R4)2; vii) -[C(R11)2]nCON(R4)2 ; viii) -[C(R11)2]nCONR4N(R4)2; ix) -[C(R11)2]nCN; x) -[C(R11)2]nCNO; xi) -[C(R11)2]nCF3, -[C(R11)2]nCCl3, -[C(R11)2]nCBr3; xii) -[C(R11)2]nN(R4)2; xiii) -[C(R11)2]nNR4COR4 ; xiv) -[C(R11)2]NR4CN; xv) -[C(R11)2]nNR4C(=NR4)N(R4)2; xvi) -[C(R11)2]nNHN(R4)2; xvii) -[C(R11)2]nNHOR4; xviii) -[C(R11)2]nNCS; xix) -[C(R11)2]nNO2; xx) -[C(R11)2]nOR4; xxi) -[C(R11)2]nOCN ; xxii) -[C(R11)2]nOCF3, -[C(R11)2]nOCCl3, -[C(R11)2]nOCBr3; xxiii) F, Cl, Br, I, y mezclas de estos; xxiv) -[C(R11)2]nSO3M; xxv) -[C(R11)nOSO3M; xxvi) -[C(R11)2]nSCN; xxvii) -[C(R11)]nSO2N(R4)2; xxviii) -[C(R11)2]nSO2R4; xxix) -[C(R11)]nP(O)(OR4)R4; xxx) -[C(R11)]nP(O)(OR4)2; xxxi) haloalquilo que tiene la fórmula -[C(R9)2]nC(R9)3; xxxii) y mezclas de estos; R8 se selecciona del grupo que consiste de: i) hidrógeno; ii) anillos carbocíclicos no aromáticos C3-8; iii) anillos carbocíclicos aromáticos C6-14; iv) anillos heterocíclicos no aromáticos C1-7; v) anillos heterocíclicos aromáticos C3-13; vi) -C(Y)R4; vii) -C(Y)2R; viii) -C(Y)N(R4)2; ix) -C(Y)NR4N(R4)2; x) -CN; xi) -CNO; xii) -[C(R9)2]C(R9)2; xiii) -N(R4)2; xiv) -NR4CN; xv) -NR4C(Y)R4; xvi) -NR4C(Y)N(R4)2; xvii) -NHN(R4)2; xviii) -NHOR4; xix) -NCS; xx) -NO2; xxi) -OR4; xxii) -OCN; xxiii) -OCF3, -OCCI3, -OCBr3; xxiv) -F, -Cl, -Br, -I, y mezclas de estos; xxv) -SCN; xxvi) -SO3M; xxvii) -OSO3M; xxviii) -SO2N(R4)2; xxix) -SO2R4 ; xxx) -[C(R11)2]nP(O)(OR4)R4; xxxi) -[C(R11)2]nP(O)(OR4)2; xxxii) y mezclas de estos; cada R10 independientemente se selecciona de: i) -[C(R4)2]p(CH=CH)qR4; en donde p es de 0 a 12; q es de 0 a 12; ii) -C(X)R4; iii) -C(X)2R4; iv) -C(X)CH=CH2; v)-C(X)N(R4)2; vi) -C(X)NR4N(R4)2; vii) -CN; viii) -CNO; ix) -CF3, -CCl3, -CBr3; x) -N(R4)2; xi) -NR4CN; xii) -NR4C(X)R4; xiii) -NR4C(X)N(R4)2; xiv) -NHN(R4)2; xv) -NHOR4; xvi) -NCS; xvii) -NO2; xviii) -OR4; xix) -OCN; xx) -OCF3, -OCCl3, -OCBr3; xxi) -F, -Cl, -Br, -I, y mezclas de estos; xxii) -SCN; xxiii) -SO3M; xxiv) -OSO3M; xxv)-SO2N(R4)2; xxvi) -SO2R4; xxvii) -[C(R11)2]nP(O)(OR4)R4; xxviii) -[C(R11)2]n P(O)(OR4)2 ; xxix) y mezclas de estos; en donde M es hidrógeno, ó un catión formador de sal. Una composición que comprende uno o más de dichos compuestos, incluyendo todas las formas enantioméricas y diastereoméricas y las sales farmacéuticamente aceptables de éstas, y uno o más excipientes farmacéuticamente aceptables. Método para controlar el apetito en humanos y mamíferos superiores administrándoles una composición que comprende uno o más de dichos compuestos y método para controlar uno o más trastornos mediados por MC-4 en un humano, dichos trastornos se seleccionan del grupo que consiste de resistencia a la insulina intolerancia a la glucosa, diabetes mellitus Tipo-2 y enfermedad de arteria coronaria. Método para controlar condiciones de comportamiento, de
ARP030103859A 2002-10-23 2003-10-22 Derivados de piperazina que actuan como ligandos receptores de melanocortina y composiciones farmaceuticas que los contienen para controlar trastornos mediados por mc-4 AR043054A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42057802P 2002-10-23 2002-10-23

Publications (1)

Publication Number Publication Date
AR043054A1 true AR043054A1 (es) 2005-07-13

Family

ID=32176593

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103859A AR043054A1 (es) 2002-10-23 2003-10-22 Derivados de piperazina que actuan como ligandos receptores de melanocortina y composiciones farmaceuticas que los contienen para controlar trastornos mediados por mc-4

Country Status (18)

Country Link
US (2) US7132539B2 (es)
EP (1) EP1556361A2 (es)
JP (1) JP2006506384A (es)
KR (1) KR20050072445A (es)
CN (1) CN1703221A (es)
AR (1) AR043054A1 (es)
AU (1) AU2003286557A1 (es)
BR (1) BR0315614A (es)
CA (1) CA2501231A1 (es)
MA (1) MA27478A1 (es)
MX (1) MXPA05004378A (es)
NO (1) NO20052476L (es)
PE (1) PE20040778A1 (es)
PL (1) PL376702A1 (es)
RU (1) RU2005111967A (es)
TW (1) TW200504033A (es)
WO (1) WO2004037797A2 (es)
ZA (1) ZA200502944B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005274701A1 (en) 2004-07-19 2006-02-23 Merck Sharp & Dohme Corp. Acylated piperidine derivatives as melanocortin-4 receptor agonists
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR101478253B1 (ko) * 2007-09-17 2014-12-31 국민대학교산학협력단 아룸 팔래스티눔(Ａｒｕｍ ｐａｌａｅｓｔｉｎｕｎＢｏｉｓｓ) 유래 항암용 피페라지움 화합물
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
EP2358200A4 (en) 2008-11-17 2012-05-16 Merck Sharp & Dohme BICYCLIC AMINES SUBSTITUTED FOR THE TREATMENT OF DIABETES
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011011508A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
UY32826A (es) 2009-08-04 2011-02-28 Takeda Pharmaceutical Compuestos heterocíclicos
EP2470552B1 (en) 2009-08-26 2013-11-13 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US8785634B2 (en) 2010-04-26 2014-07-22 Merck Sharp & Dohme Corp Spiropiperidine prolylcarboxypeptidase inhibitors
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US9321749B1 (en) 2012-07-25 2016-04-26 Globavir Biosciences, Inc. Heterocyclic compounds and uses thereof
PT3333165T (pt) * 2015-08-04 2019-10-29 Astellas Pharma Inc Derivado de piperazina

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4251438A (en) 1979-06-14 1981-02-17 The Upjohn Company Piperazinone and piperazine polypeptides
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
RU2168512C2 (ru) 1992-12-11 2001-06-10 Мерк Энд Ко., Инк. Спиропиперидины, способы их получения (варианты)
US5556853A (en) * 1993-10-29 1996-09-17 Takeda Chemical Industries, Ltd. Epoxysuccinic acid derivatives
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5494919A (en) 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5721251A (en) 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
AU3128195A (en) 1994-07-20 1996-02-16 Merck & Co., Inc. Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone
US5767118A (en) 1994-10-26 1998-06-16 Merck & Co., Inc. 4-Heterocyclic peperidines promote release of growth hormone
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
ATE288444T1 (de) 1995-05-29 2005-02-15 Pfizer Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
GB9612276D0 (en) 1996-06-12 1996-08-14 Merck & Co Inc 4-Spiroindoline piperidines promote release of growth hormone
US5804578A (en) 1996-04-03 1998-09-08 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
WO1998010653A1 (en) 1996-09-13 1998-03-19 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US5877182A (en) 1996-09-13 1999-03-02 Merck & Co., Inc. Piperidines promote release of growth hormone
US5965565A (en) 1996-12-12 1999-10-12 Merck & Co., Inc. Piperidines promote release of growth hormone
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
EP1076649A4 (en) 1998-04-28 2010-06-02 Trega Biosciences Inc ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE
EP1077941B1 (en) 1998-05-11 2009-08-12 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6294534B1 (en) 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
JP2002517444A (ja) 1998-06-11 2002-06-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作動薬としてのスピロピペリジン誘導体
AU754529B2 (en) 1998-09-22 2002-11-21 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
BR0010304A (pt) 1999-05-04 2002-02-13 Schering Corp Derivados de piperazina úteis como antagonistas do ccr5
CA2377369A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
AU6000200A (en) 1999-07-16 2001-02-05 Biocompatibles Limited Braided stent
EP1268449A4 (en) 2000-03-23 2004-09-15 Merck & Co Inc SUBSTITUTED PIPERIDINE AS MELANOCORTIN RECEPTOR AGONISTS
AU2001249281B2 (en) 2000-03-23 2005-01-27 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
AU6497701A (en) 2000-05-30 2001-12-11 Merck & Co Inc Melanocortin receptor agonists
EA200201119A1 (ru) 2000-06-28 2003-06-26 Пфайзер Продактс Инк. Лиганды меланокортиновых рецепторов
US6767915B2 (en) 2000-08-23 2004-07-27 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
WO2002059095A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Melanocortin receptor agonists
JP2004521117A (ja) 2001-01-23 2004-07-15 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニストとしての置換ピペリジン／ピペラジン
JP2004523530A (ja) 2001-01-23 2004-08-05 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニストとしてのピペラジンおよびピペリジン誘導体
MXPA03007785A (es) 2001-02-28 2003-12-08 Merck & Co Inc Derivados de piperidina acilados como agonistas del receptor de melanocortina 4.
DE60215132T2 (de) 2001-02-28 2007-08-23 Merck & Co., Inc. Acylierte piperidin-derivate als melanocortin-4-rezeptor-agonisten
CA2438272A1 (en) 2001-03-02 2002-10-10 John Macor Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
US6720325B2 (en) 2001-03-29 2004-04-13 Schering Corporation CCR5 antagonists useful for treating aids
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
EP1425029A4 (en) 2001-08-10 2006-06-07 Palatin Technologies Inc PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES
EP1423381B1 (en) 2001-09-06 2007-01-03 Schering Corporation 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
EP1465867A1 (en) * 2001-10-09 2004-10-13 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
JP2005507923A (ja) 2001-10-22 2005-03-24 ファイザー・プロダクツ・インク Ｃｃｒ１受容体アンタゴニスト活性を有するピペラジン誘導体
ES2274201T3 (es) 2002-01-23 2007-05-16 Eli Lilly And Company Agonistas del receptor de melanocortina.

Also Published As

Publication number Publication date
AU2003286557A1 (en) 2004-05-13
WO2004037797A2 (en) 2004-05-06
MA27478A1 (fr) 2005-08-01
WO2004037797A3 (en) 2004-11-04
CN1703221A (zh) 2005-11-30
PE20040778A1 (es) 2004-12-21
BR0315614A (pt) 2005-08-30
RU2005111967A (ru) 2006-01-20
US20060247224A1 (en) 2006-11-02
US20050010031A1 (en) 2005-01-13
NO20052476D0 (no) 2005-05-23
EP1556361A2 (en) 2005-07-27
US7132539B2 (en) 2006-11-07
MXPA05004378A (es) 2005-07-05
KR20050072445A (ko) 2005-07-11
ZA200502944B (en) 2006-02-22
PL376702A1 (pl) 2006-01-09
NO20052476L (no) 2005-05-23
CA2501231A1 (en) 2004-05-06
JP2006506384A (ja) 2006-02-23
TW200504033A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
AR043054A1 (es) Derivados de piperazina que actuan como ligandos receptores de melanocortina y composiciones farmaceuticas que los contienen para controlar trastornos mediados por mc-4
JP2018523665A5 (es)
AR035863A1 (es) Ligandos receptores de melanocortina
AR078152A1 (es) Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden
AR077239A1 (es) Prodrogas de compuestos n-acidicos utiles en el tratamiento de trastornos neurologicos y psiquiatricos, tales como esquizofrenia y trastorno bipolar.
DK0773930T3 (da) Aromatiske aminoethere som midler til lindring af smerte
AR031680A1 (es) Utilizacion de acrilamidas de quinuclidina para la preparacion de medicamentos, compuestos y composicion farmaceutica
BR0317458A (pt) EnanciÈmero-s, composto, formulação farmacêutica, método para tratar ou previnir distúrbios de lipìdeos (dislipdemia) associados ou não com resistência à insulina, uso de um composto, método para tratar ou previnir diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica
AR053082A1 (es) DERIVADOS 8-PERFLUOROALQUIL-6,7,8,9-TETRAHIDROPIRIMIDO[1,2-A]PIRIMIDIN-4-ONA SUBSTITUIDOS NHIBIDORES DE GSK3BETA Y SU EMPLEO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS.
CA2571984A1 (en) Antiviral compounds
AR032436A1 (es) Oxazolidinonas substituidas, procedimiento para su preparacion, medicamentos, el uso de las mismas para la fabricacion de medicamentos, y el metodo para impedir la coagulacion sanguinea in vitro
DE69805781D1 (de) Substituierte 4-arylmethylene-2-imino-2,3-dihydrothiazolen, ihre derivaten, und ihre pharmazeutische verwendung
AR019842A1 (es) Derivados de nafto[2,3-b]heteroar-4-ilo, el uso de los mismos para la manufactura de un medicamento y una composicion que los comprende.
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
BR9508900A (pt) Derivado heterocíclico e medicamento
TNSN91068A1 (fr) Nouveaux sulfonamides substitues. procedes de preparation et medicaments les contenant.
AR016431A1 (es) Derivados de piperidina, un proceso para su preparacion, medicamentos que los comprenden y el uso de dichos derivados para la manufactura de un medicamento
ATE363279T1 (de) Thiazol-imidazol- und oxazolverbindungen und behandlung von mit proteinalterung verbundenen erkrankungen
AR039780A1 (es) Ligandos receptores de melanocortina
JP4620244B2 (ja) シナプス反応を高めるベンゾキサジン化合物
FR2645537B1 (fr) Nouveaux sulfonamides derives d'acides benzocycliques ou benzoheterocycliques, leur preparation et leur application en therapeutique
DK0456209T3 (da) Bis(alkylsubstituerede-4-hydroxyphenylthio)alkananaloger som inhibitorer af kataraktdannelse
FR2683819B1 (fr) Derives de quinoleine, leur procede de preparation et leur application en therapeutique.
AR039779A1 (es) Ligandos receptores de melanocortina y composicion farmaceutica que contiene el compuesto
AR063417A1 (es) Compuestos inhibidores del activador de plasminogeno tipo 1(pai-1)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal